PURPOSE: Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot open-labeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CD patients who have undergone multiple surgeries due to penetrating disease. METHODS: Eleven patients (nine male, two female; age range, 26-48 years) who had undergone repeated surgeries (median, 4; range, 2-5) for penetrating disease were enrolled. Two to 4 weeks after surgery, the patients were started on intravenous infliximab (5 mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/radiologic remission at 24 months, and the rate of adverse effects. RESULTS: One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0%) at the end of the study. At 24 months, four out of ten patients were in endoscopic or radiological remission (40.0%). Two patients experienced adverse effects (18.2%), one of whom elected to withdraw from the study. CONCLUSION: The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted.
PURPOSE:Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot open-labeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CDpatients who have undergone multiple surgeries due to penetrating disease. METHODS: Eleven patients (nine male, two female; age range, 26-48 years) who had undergone repeated surgeries (median, 4; range, 2-5) for penetrating disease were enrolled. Two to 4 weeks after surgery, the patients were started on intravenous infliximab (5 mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/radiologic remission at 24 months, and the rate of adverse effects. RESULTS: One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0%) at the end of the study. At 24 months, four out of ten patients were in endoscopic or radiological remission (40.0%). Two patients experienced adverse effects (18.2%), one of whom elected to withdraw from the study. CONCLUSION: The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted.
Authors: Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Miguel Regueiro; Wolfgang Schraut; Leonard Baidoo; Kevin E Kip; Antonia R Sepulveda; Marilyn Pesci; Janet Harrison; Scott E Plevy Journal: Gastroenterology Date: 2008-10-31 Impact factor: 22.682
Authors: Emanuelle Bellaguarda; Kian Keyashian; Joel Pekow; David T Rubin; Russell D Cohen; Atsushi Sakuraba Journal: Clin Gastroenterol Hepatol Date: 2015-05-19 Impact factor: 11.382
Authors: C Seifarth; J P Ritz; U Pohlen; A J Kroesen; B Siegmund; B Frericks; H J Buhr Journal: Int J Colorectal Dis Date: 2014-05-04 Impact factor: 2.571